Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
TACE Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%. Despite a significant improvement in treatment strategy, the overall survival of HCC remains low due to high recurrence, progressive liver dysfunction and …

hepatocellular carcinoma
monoclonal antibodies
TACE
sorafenib
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed

refractory acute myeloid leukemia (aml)
leukemia
myelodysplastic syndromes
myeloid leukemia
azacitidine
  • 0 views
  • 11 Mar, 2022
  • 2 locations
LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Prevention

Introduction: There are several manifestations in the oral mucosa resulting from antineoplastic treatments by chemo (QT) or radiotherapy (RT). In this study we will collect the variables

mucositis
antineoplastic
  • 0 views
  • 22 Mar, 2022
  • 1 location
Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

This is a Phase 1/2, open-label study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of single-agent BLU-451. All patients will receive BLU-451 as a single agent administered once daily (QD) or twice daily (BID) on a 21-day treatment cycle.

  • 0 views
  • 26 Apr, 2022
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

PARP inhibitors have changed the treatment paradigm of ovarian cancer. Most patients using PARP(poly-ADP ribose polymerase) inhibitors will suffer different grades of adverse events(AEs), followed by dose reduction. It has not been reported whether the dose-reduced olaparib as maintenance treatment have an impact on efficacy. Both PAOLA-1 and AVANOVA 2 …

kinase inhibitor
cancer chemotherapy
recurrent ovarian cancer
ovarian cancer
chemotherapy regimen
  • 5 views
  • 27 Jan, 2021
  • 1 location
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced

estrogen receptor
erbb2
estrogen
HER2
fulvestrant
  • 0 views
  • 25 Mar, 2022
  • 5 locations
Study of Diagnostic Performance of [18F]CTT1057 in BCR (GuidePath)

[18F]CTT1057 PET/CT scan imaging, and at least one evaluable CTS assessment and have not received any prohibited systemic antineoplastic therapy before the completion of PET/CTs and CTS procedures

  • 0 views
  • 13 Jun, 2022
  • 7 locations
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the incidence of severe oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving …

dental caries
mouth cancer
mucositis
squamous cell carcinoma of the oral cavity
carcinoma
  • 1 views
  • 25 Mar, 2022
  • 8 locations
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

osimertinib
cancer chemotherapy
chemotherapy regimen
progressive disease
platinum-based chemotherapy
  • 0 views
  • 12 May, 2022
  • 5 locations
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits tumor angiogenesis and is also recommended for the treatment of recurrent ovarian cancer. Clinical …

cancer chemotherapy
recurrent ovarian cancer
chemotherapy regimen
platelet count
monoclonal antibodies
  • 0 views
  • 26 Jan, 2021
  • 1 location